News Updates
Scope
Catalyst

Tue, May 12, 2026

1 updates
MANE
7:30 AM

Veradermics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

Positive topline results from Phase 2/3 Study ‘302’ position VDPHL01 to potentially become the first FDA-approved oral treatment for pattern hair loss in nearly 30 years Upsized IPO and follow-on financing generated approximately $766.8 million in aggregate gross proceeds; pro forma cash expected

Trial Results • Phase 2/3Study 302 Part A topline results Wed, Apr 1, 2026veradermics.com

Mon, Apr 27, 2026

1 updates
MANE
7:00 AM

Veradermics’ Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 2/3 ‘302’ Clinical Trial in Male Pattern Hair Loss

VDPHL01, a novel orally-administered extended-release minoxidil formulation, met all primary and all key secondary endpoints with high statistical significance in both active treatment arms evaluating once-daily (QD) and twice-daily (BID) administration of VDPHL01 Rapid and robust hair growth was

Trial Results • Phase 2/3veradermics.com